The pharmacogenetics of methotrexate
- PMID: 17586865
- DOI: 10.1093/rheumatology/kem147
The pharmacogenetics of methotrexate
Abstract
Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately. Pharmacogenetics is the study of variability in drug response due to heredity. MTX has a complex intracellular metabolism and acts via a number of key enzymes. This review critically appraises the studies of MTX pharmacogenetics and highlights the need for further work in this area.
Comment in
-
Comment on: The pharmacogenetics of methotrexate.Rheumatology (Oxford). 2008 Apr;47(4):557; author reply 5557-8. doi: 10.1093/rheumatology/kem386. Epub 2008 Jan 25. Rheumatology (Oxford). 2008. PMID: 18222982 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
